The Experts below are selected from a list of 597 Experts worldwide ranked by ideXlab platform
Andrew Pannifer - One of the best experts on this subject based on the ideXlab platform.
-
corrigendum to design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of pi3kα and mtor bioorg med chem lett 22 2012 5098 5103
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Michael Bruno Plewe, Caroline Lafleur M Rogers, Andrew PanniferAbstract:Corrigendum Corrigendum to ‘‘Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Ka and mTOR’’ [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103] Phuong T. Le a,⇑, Hengmiao Cheng , Sacha Ninkovic , Michael Plewe , Xiaojun Huang , Hai Wang , Shubha Bagrodia , Shaoxian Sun , Daniel R. Knighton , Caroline M. LaFleur Rogers , Andrew Pannifer , Samantha Greasley , Deepak Dalvie , Eric Zhang c Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States Oncology Research Unit, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States PDM, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States d Pfizer Worldwide Research & Development, Sandwich Laboratories, Pfizer Inc., UK
Hengmiao Cheng - One of the best experts on this subject based on the ideXlab platform.
-
corrigendum to design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of pi3kα and mtor bioorg med chem lett 22 2012 5098 5103
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Michael Bruno Plewe, Caroline Lafleur M Rogers, Andrew PanniferAbstract:Corrigendum Corrigendum to ‘‘Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Ka and mTOR’’ [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103] Phuong T. Le a,⇑, Hengmiao Cheng , Sacha Ninkovic , Michael Plewe , Xiaojun Huang , Hai Wang , Shubha Bagrodia , Shaoxian Sun , Daniel R. Knighton , Caroline M. LaFleur Rogers , Andrew Pannifer , Samantha Greasley , Deepak Dalvie , Eric Zhang c Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States Oncology Research Unit, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States PDM, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States d Pfizer Worldwide Research & Development, Sandwich Laboratories, Pfizer Inc., UK
-
Corrigendum to “Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Kα and mTOR” [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103]
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Plewe Michael Bruno, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Caroline M. Lafleur RogersAbstract:Corrigendum Corrigendum to ‘‘Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Ka and mTOR’’ [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103] Phuong T. Le a,⇑, Hengmiao Cheng , Sacha Ninkovic , Michael Plewe , Xiaojun Huang , Hai Wang , Shubha Bagrodia , Shaoxian Sun , Daniel R. Knighton , Caroline M. LaFleur Rogers , Andrew Pannifer , Samantha Greasley , Deepak Dalvie , Eric Zhang c Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States Oncology Research Unit, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States PDM, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States d Pfizer Worldwide Research & Development, Sandwich Laboratories, Pfizer Inc., UK
-
Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Kα and mTOR.
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Plewe Michael Bruno, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Caroline M. Lafleur RogersAbstract:Lead optimization efforts that employed structure base drug design and physicochemical property based optimization leading to the discovery of a novel series of 4-methylpyrido Pyrimidinone (MPP) are discussed. Synthesis and profile of 1, a PI3Kα/mTOR dual inhibitor, is highlighted.
Sacha Ninkovic - One of the best experts on this subject based on the ideXlab platform.
-
corrigendum to design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of pi3kα and mtor bioorg med chem lett 22 2012 5098 5103
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Michael Bruno Plewe, Caroline Lafleur M Rogers, Andrew PanniferAbstract:Corrigendum Corrigendum to ‘‘Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Ka and mTOR’’ [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103] Phuong T. Le a,⇑, Hengmiao Cheng , Sacha Ninkovic , Michael Plewe , Xiaojun Huang , Hai Wang , Shubha Bagrodia , Shaoxian Sun , Daniel R. Knighton , Caroline M. LaFleur Rogers , Andrew Pannifer , Samantha Greasley , Deepak Dalvie , Eric Zhang c Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States Oncology Research Unit, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States PDM, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States d Pfizer Worldwide Research & Development, Sandwich Laboratories, Pfizer Inc., UK
-
Corrigendum to “Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Kα and mTOR” [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103]
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Plewe Michael Bruno, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Caroline M. Lafleur RogersAbstract:Corrigendum Corrigendum to ‘‘Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Ka and mTOR’’ [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103] Phuong T. Le a,⇑, Hengmiao Cheng , Sacha Ninkovic , Michael Plewe , Xiaojun Huang , Hai Wang , Shubha Bagrodia , Shaoxian Sun , Daniel R. Knighton , Caroline M. LaFleur Rogers , Andrew Pannifer , Samantha Greasley , Deepak Dalvie , Eric Zhang c Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States Oncology Research Unit, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States PDM, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States d Pfizer Worldwide Research & Development, Sandwich Laboratories, Pfizer Inc., UK
-
Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Kα and mTOR.
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Plewe Michael Bruno, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Caroline M. Lafleur RogersAbstract:Lead optimization efforts that employed structure base drug design and physicochemical property based optimization leading to the discovery of a novel series of 4-methylpyrido Pyrimidinone (MPP) are discussed. Synthesis and profile of 1, a PI3Kα/mTOR dual inhibitor, is highlighted.
Xiaojun Huang - One of the best experts on this subject based on the ideXlab platform.
-
corrigendum to design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of pi3kα and mtor bioorg med chem lett 22 2012 5098 5103
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Michael Bruno Plewe, Caroline Lafleur M Rogers, Andrew PanniferAbstract:Corrigendum Corrigendum to ‘‘Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Ka and mTOR’’ [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103] Phuong T. Le a,⇑, Hengmiao Cheng , Sacha Ninkovic , Michael Plewe , Xiaojun Huang , Hai Wang , Shubha Bagrodia , Shaoxian Sun , Daniel R. Knighton , Caroline M. LaFleur Rogers , Andrew Pannifer , Samantha Greasley , Deepak Dalvie , Eric Zhang c Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States Oncology Research Unit, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States PDM, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States d Pfizer Worldwide Research & Development, Sandwich Laboratories, Pfizer Inc., UK
-
Corrigendum to “Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Kα and mTOR” [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103]
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Plewe Michael Bruno, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Caroline M. Lafleur RogersAbstract:Corrigendum Corrigendum to ‘‘Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Ka and mTOR’’ [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103] Phuong T. Le a,⇑, Hengmiao Cheng , Sacha Ninkovic , Michael Plewe , Xiaojun Huang , Hai Wang , Shubha Bagrodia , Shaoxian Sun , Daniel R. Knighton , Caroline M. LaFleur Rogers , Andrew Pannifer , Samantha Greasley , Deepak Dalvie , Eric Zhang c Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States Oncology Research Unit, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States PDM, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States d Pfizer Worldwide Research & Development, Sandwich Laboratories, Pfizer Inc., UK
-
Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Kα and mTOR.
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Plewe Michael Bruno, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Caroline M. Lafleur RogersAbstract:Lead optimization efforts that employed structure base drug design and physicochemical property based optimization leading to the discovery of a novel series of 4-methylpyrido Pyrimidinone (MPP) are discussed. Synthesis and profile of 1, a PI3Kα/mTOR dual inhibitor, is highlighted.
Hai Wang - One of the best experts on this subject based on the ideXlab platform.
-
corrigendum to design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of pi3kα and mtor bioorg med chem lett 22 2012 5098 5103
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Michael Bruno Plewe, Caroline Lafleur M Rogers, Andrew PanniferAbstract:Corrigendum Corrigendum to ‘‘Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Ka and mTOR’’ [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103] Phuong T. Le a,⇑, Hengmiao Cheng , Sacha Ninkovic , Michael Plewe , Xiaojun Huang , Hai Wang , Shubha Bagrodia , Shaoxian Sun , Daniel R. Knighton , Caroline M. LaFleur Rogers , Andrew Pannifer , Samantha Greasley , Deepak Dalvie , Eric Zhang c Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States Oncology Research Unit, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States PDM, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States d Pfizer Worldwide Research & Development, Sandwich Laboratories, Pfizer Inc., UK
-
Corrigendum to “Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Kα and mTOR” [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103]
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Plewe Michael Bruno, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Caroline M. Lafleur RogersAbstract:Corrigendum Corrigendum to ‘‘Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Ka and mTOR’’ [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103] Phuong T. Le a,⇑, Hengmiao Cheng , Sacha Ninkovic , Michael Plewe , Xiaojun Huang , Hai Wang , Shubha Bagrodia , Shaoxian Sun , Daniel R. Knighton , Caroline M. LaFleur Rogers , Andrew Pannifer , Samantha Greasley , Deepak Dalvie , Eric Zhang c Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States Oncology Research Unit, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States PDM, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States d Pfizer Worldwide Research & Development, Sandwich Laboratories, Pfizer Inc., UK
-
Design and synthesis of a novel pyrrolidinyl pyrido Pyrimidinone Derivative as a potent inhibitor of PI3Kα and mTOR.
Bioorganic & Medicinal Chemistry Letters, 2012Co-Authors: Hengmiao Cheng, Sacha Ninkovic, Plewe Michael Bruno, Xiaojun Huang, Hai Wang, Shubha Bagrodia, Shaoxian Sun, Daniel R. Knighton, Caroline M. Lafleur RogersAbstract:Lead optimization efforts that employed structure base drug design and physicochemical property based optimization leading to the discovery of a novel series of 4-methylpyrido Pyrimidinone (MPP) are discussed. Synthesis and profile of 1, a PI3Kα/mTOR dual inhibitor, is highlighted.
